Prime Medicine (NYSE:PRME) Receives “Neutral” Rating from Citigroup
Prime Medicine (NYSE:PRME – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Citigroup in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $1.50 price objective on the stock, down from their prior price objective of $10.00. Citigroup’s price target would indicate a potential upside […]
Prime Medicine (NYSE:PRME – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Citigroup in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $1.50 price objective on the stock, down from their prior price objective of $10.00. Citigroup’s price target would indicate a potential upside […]
